MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with diet and exercise alone, others find that adding weight loss medications like ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that lots of patients had stopped taking Amgen’s experimental weight loss shot ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

A monthly dose of a new drug called MariTide helped participants in a phase 2 clinical trial shed about 20% of their body weight over a year, researchers reported Monday in The New England Journal ...

Maridebart cafraglutide (Amgen), also known as MariTide or AMG133, helps patients with obesity—whether or not they also have diabetes—lose substantial amounts of body weight, according to newly ...

Amgen's new drug MariTide shows promise in obesity treatment, with participants losing up to 16% body weight in a year with monthly shots.

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.